International Journal of Biological Markers最新文献

{"title":"Association between serum uric acid and the risk of breast cancer: A meta-analysis of observational studies.","authors":"Liping Yang, Ziyun Yu, Jin Zhu, Longbo He, Lieliang Wang, Qingfeng Luo","doi":"10.1177/03936155241313469","DOIUrl":"10.1177/03936155241313469","url":null,"abstract":"<p><p>BackgroundThe relationship between serum uric acid and breast cancer remains uncertain. This meta-analysis aimed to elucidate the dose-response association between elevated serum uric acid levels and breast cancer risk.MethodsWe systematically searched PubMed, Embase, and Web of Science for observational studies evaluating serum uric acid and breast cancer risk in adult women. Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using a random-effects model.ResultsTen studies were included. High serum uric acid was associated with an increased breast cancer risk (RR: 1.34; 95% CI: 1.03-1.73; <i>P</i> = 0.03; I² = 78%). Meta-regression analysis revealed that the cutoff for high serum uric acid positively correlated with breast cancer risk (coefficient = 0.24; <i>P</i> < 0.001), explaining heterogeneity (residual I² = 0%). Subgroup analysis demonstrated a high serum uric acid was significantly related to an increased breast cancer risk in studies with a cutoff value ≥ 5.4 mg/dL (RR: 1.95; <i>P</i> < 0.001), but not in those with a cutoff value < 5.4 mg/dL (RR: 0.97; <i>P</i> = 0.44). The dose-response meta-analysis revealed a U-shaped association between serum uric acid levels and the risk of breast cancer (<i>P</i> for nonlinearity = 0.013). The risk of breast cancer fell until around 4.5 mg/dL of serum uric acid, and increased afterward.ConclusionSerum uric acid may be nonlinearly associated with the risk of breast cancer (U-shaped). The risk of breast cancer increases with serum uric acid above 4.5 mg/dL, and a higher association between serum uric acid and the increased risk of breast cancer could be observed in studies with cutoff of serum uric acid  > 5.4 mg/dL.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":" ","pages":"35-45"},"PeriodicalIF":2.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143469726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular residual disease assessment based on tumor-informed assay predict disease progression and postoperative recurrence of hepatobiliary cancer: A preliminary study.","authors":"Xiaobing Zhang, Huiguo Shan, Hongyu Pan, Qian Zhong, Qiang Fang, Yun Xu, Yun Liu, Shuping Qu","doi":"10.1177/03936155251315500","DOIUrl":"10.1177/03936155251315500","url":null,"abstract":"<p><p>BackgroundHepatobiliary cancers present a heterogeneous group of diseases, and molecular residual disease (MRD) evaluation based on circulating tumor DNA (ctDNA) is anticipated to offer greater sensitivity in monitoring disease progression than glycoprotein-based tumor markers such as alpha-fetoprotein or carbohydrate antigen 19-9 (CA199).MethodsThe panels for MRD surveillance were customized for each patient based on their specific genetic mutation characteristics. The changes in ctDNA mean variant allele frequencies (mVAF) and single nucleotide variants (SNVs) were analyzed from baseline to post-operative and between post-operative measurements.ResultsA unique tumor-informed whole-exome sequencing (WES) assay revealed significant variations in gene mutations between individuals. Among 63 cases, a total of 1952 SNVs were detected in tumor tissue from 63 patients using WES; only 6 loci (0.3%) were shared by at least 2 patients, indicating that over 95% of the 20-40 loci screened were unique to individual patients . Only 17 gene alterations were common to at least 2 patients, suggesting that alterations vary widely between individuals. The mVAF and the number of SNVs in ctDNA at baseline was dramatically higher than in first post-operative MRD (MRD1). The mVAF clearance was observed in three patients, whose ctDNA was positive at MRD1 but subsequently became negative at the second post-operative MRD (MRD2). Patients exhibiting vascular invasion demonstrated a significant increase in mVAF levels and SNV numbers. Furthermore, we revealed that mVAF levels were significantly associated with clinicopathologic characteristics, including gender, age, tumor subtype, stage, metastasis, vascular invasion, hepatitis B, liver cirrhosis, and tumor differentiation. Importantly, we have shown that the detection of an MRD-guided medication regimen modification is crucial to achieve clinical complete remission.ConclusionsThis study provided data supporting the use of a more reliable assay for MRD analysis in hepatobiliary cancers based on a tumor-informed assay. Dynamic monitoring of post-operative MRD is important for assessing disease progression, risk of recurrence, and response to treatment.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":" ","pages":"55-66"},"PeriodicalIF":2.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143544345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic value of microRNA-129-5p and TSH combination for papillary thyroid cancer with cervical lymph node metastasis.","authors":"Yi Shen, Rongli Xie, Yupan Chen, Xujie Han, Xiao-En Li","doi":"10.1177/03936155241303763","DOIUrl":"10.1177/03936155241303763","url":null,"abstract":"<p><p>ObjectiveThe papillary thyroid cancer (PTC) incidence is on the increase. We explored the diagnostic value of microRNA (miR)-129-5p & serologic indicator thyroid-stimulating hormone (TSH) test in PTC with cervical lymph node metastasis (LNM).MethodsAccording to the pathological \"gold standard,\" 198 PTC patients were assigned into the LNM (n = 93)/non-LNM (n = 105) groups, with their medical records collected. The serum free-triiodothyronine (FT3)/free-thyroxine (FT4)/TSH/thyroglobulin (Tg)/thyroglobulin antibody levels were assessed using an electrochemiluminescence immunoassay device. Serum miR-129-5p expression was determined by reverse transcription quantitative polymerase chain reaction. Correlations between serum miR-129-5p/TSH levels with pathological indicators were analyzed by Spearman correlation coefficient. Independent influencing factors for cervical LNM in PTC patients was analyzed by logistic multivariate regression analysis. Diagnostic value of miR-129-5p combined with serologic indicator TSH test in PTC patients with cervical LNM and lateral cervical LNM was analyzed by the receiver operating characteristic curve.ResultsThe two groups varied obviously in primary tumor size/Tg level. Serum miR-129-5p expression in the LNM group was reduced, and negatively correlated with Tg and primary tumor size, while the serologic indicator TSH level showed positive correlations with Tg and primary tumor size. Independent influencing factors for PTC with cervical LNM were miR-129-5p/TSH/Tg levels. miR-129-5p and serologic indicator TSH levels had high diagnostic value for PTC patients with cervical LNM and lateral cervical LNM, with their combination showing higher diagnostic value.ConclusionmiR-129-5p and serologic indicator TSH had high diagnostic value for diagnosing PTC patients with cervical LNM, providing high reference value for the formulation of thyroid tumor resection.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":" ","pages":"46-54"},"PeriodicalIF":2.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alcohol dehydrogenase iron containing 1 (<i>ADHFE1</i>) is associated with liver metastasis and regulates cellular function of gastric cancer.","authors":"Ling Qin, Fei Liu, Chen Sun, Zhang Zhang, Lingling Sun, Xingli Tang, Yunhong Xia","doi":"10.1177/03936155251319784","DOIUrl":"10.1177/03936155251319784","url":null,"abstract":"<p><p>BackgroundLiver metastasis and chemotherapy resistance are two unfavorable factors for the outcomes of gastric cancer patients. <i>ADHFE1</i> was identified as cancer-related molecule and candidate for early detection in gastric cancer. This study evaluated the significance of <i>ADHFE1</i> in gastric cancer, aiming to explore a potential biomarker and therapeutic target for gastric cancer.MethodsThe expression of <i>ADHFE1</i> was detected by polymerase chain reaction and compared between 143 gastric cancer patients and 54 individuals with benign lesions. The role of <i>ADHFE1</i> in gastric cancer development and prognosis was assessed. The effect of <i>ADHFE1</i> on gastric cancer cell growth and motility was evaluated by cell counting kit-8 and Transwell assay. The angiogenesis and cisplatin resistance were assessed by related markers and the half maximal inhibitory concentration values.ResultsSignificant upregulation of <i>ADHFE1</i> was observed in gastric cancer patients compared to individuals with benign lesions, which showed close association with the tumor node metastasis stage, lymph node metastasis, liver metastasis, and adverse prognosis of gastric cancer patients. Patients with liver metastasis showed higher serum <i>ADHFE1</i> levels, which decreased after chemotherapy. Silencing <i>ADHFE1</i> significantly suppressed gastric cancer cell proliferation, migration, invasion, and angiogenesis while its overexpression showed opposite effects. Moreover, the overexpression of <i>ADHFE1</i> significantly improved the cisplatin resistance of gastric cancer cells.ConclusionSerum <i>ADHFE1</i> served as an indicator for poor prognosis and liver metastasis of gastric cancer. <i>ADHFE1</i> regulates gastric cancer cell progression, cisplatin resistance, and angiogenesis, suggesting its potential to serve as a therapeutic target.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":" ","pages":"67-74"},"PeriodicalIF":2.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143469707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Urine exosomal lncRNAs as novel biomarkers for early diagnosis of bladder cancer based on microarray differential expression profiling.","authors":"Jun Li, Liming Zhao, Luning Li, Xiaohua Wang, Yisheng Gao, Yongli Gao, Jinfeng Wang","doi":"10.1177/03936155251317551","DOIUrl":"10.1177/03936155251317551","url":null,"abstract":"<p><p>PurposeWe aimed to exploit a urine exosomal long non-coding RNAs (lncRNAs) fingerprint to facilitate the early diagnosis of bladder cancer.MethodsMicroarray differential expression profiling of lncRNAs was for the first time employed in urine exosomes from 10 non-muscle-invasive bladder cancer (NMIBC) patients and 10 healthy controls to screen out candidate exosomal lncRNA biomarkers, which were then verified by quantitative real-time polymerase chain reaction in three independent phases including bladder cancer cells, culture fluid and 200 NMIBC participants. Logistic regression was performed to construct a diagnostic model-the diagnostic potency of which was assessed.ResultsThe profile of three exosome-derived lncRNAs (CCDC148-AS1, XLOC_006419, and RP5-1148A21.3) was screened and further verified to be notably over-expressed in NMIBC patients and bladder cancer cell lines, and exhibited area under the receiver-operating characteristic curve values of 0.873, 0.825, and 0.834, respectively, in training, validation, and double-blind validation phases. The profile was superior to urinary cytology in discriminating NMIBC from healthy controls (<i>P </i>< 0.0001). A significant correlation existed between a higher level of CCDC148-AS1 and a higher tumor grade (<i>P </i>< 0.001), and up-regulated CCDC148-AS1 as well as XLOC_006419 were statistically related with tumor node metastasis stage (<i>P </i>= 0.004 and <i>P </i>= 0.031, respectively). These three identified lncRNAs were confirmed to originate from bladder cancer cells and be packaged within exosomes, thus staying sufficiently stable in urine.ConclusionsTumor-originated urine exosomal lncRNAs, as fingerprint in NMIBC, exhibited satisfying clinical significance in early diagnosis of bladder cancer.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":" ","pages":"24-34"},"PeriodicalIF":2.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143411398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CircLPHN3 correlates with prognosis in colorectal cancer and regulates cellular processes by targeting miR-142-5p.","authors":"JiWen Zhang, Yan Cai","doi":"10.1177/03936155241287219","DOIUrl":"10.1177/03936155241287219","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) is often diagnosed late and has a poor prognosis. Circular RNAs (circRNAs) have been identified as prognostic biomarkers in various cancers, including CRC.</p><p><strong>Objective: </strong>The objective was to elucidate the role of circLPHN3 (hsa_circ_0069865) in CRC progression and to provide a promising prognostic marker for CRC.</p><p><strong>Methods: </strong>CircLPHN3 was identified through bioinformatics analysis of the GSE121842 dataset. The levels of circLPHN3 in CRC samples were analyzed by real time-quantitative polymerase chain reaction. Its clinical significance was assessed using the Kaplan-Meier curve and multivariate Cox regression. Downstream microRNAs of circLPHN3 were predicted with the RNAhybrid, Circular RNA Interactome, and starBase online databases. The target of miR-142-5p was predicted using miRDB, TargetScanHuman, starBase, and miRWalk databases. The relationship between circLPHN3, miR-142-5p, and LDB2 was verified by dual luciferase reporter assay. The function of circLPHN3 on CRC cell growth and metastasis was measured using Transwell and the cell counting kit-8 assay.</p><p><strong>Results: </strong>Significant downregulation of circLPHN3 was found in CRC. CircLPHN3 was closely related to higher tumor node metastasis stage, lymph node metastasis, and predicted unfavorable prognosis. miR-142-5p was highly expressed in CRC and its expression was negatively regulated by circLPHN3. Overexpression of circLPHN3 curbed CRC cell growth, migration, and invasion, mediated by miR-142-5p. Moreover, LDB2 was identified as a target of miR-142-5p.</p><p><strong>Conclusion: </strong>CircLPHN3 acted as a prognostic biomarker and tumor suppressor for CRC via modulating miR-142-5p.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":" ","pages":"292-300"},"PeriodicalIF":2.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142479636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The predictive value of miR-29b-2-5p on the prognosis of cervical cancer and its inhibitory effect on cervical cancer progression.","authors":"Qinghan Liu, Xi Chen, Wenhui Zhang, Wei Shang, Jinwei Cao, Huijuan Zhao, Feng Jian","doi":"10.1177/03936155241299429","DOIUrl":"https://doi.org/10.1177/03936155241299429","url":null,"abstract":"<p><strong>Objective: </strong>The poor prognosis of cervical cancer patients leads to an annual increase in mortality, while microRNAs are involved in various cancers, including cervical cancer. This study aimed to investigate the clinical value and possible effect of miR-29b-2-5p on the progression of cervical cancer.</p><p><strong>Methods: </strong>The expression level of miR-29b-2-5p in cervical cancer tissues and cells was analyzed by polymerase chain reaction. The Kaplan-Meier curve was used to evaluate the role of miR-29b-2-5p in cervical cancer prognosis. The independent prognostic factors of cervical cancer were explored by the multivariate Cox regression analysis. The effect of miR-29b-2-5p on the proliferation, migration, and invasion of cervical cancer cells was determined by in vitro cell experiments.</p><p><strong>Results: </strong>A significantly downregulated miR-29b-2-5p expression was observed in cervical cancer tumor tissues and cervical cancer cells compared with the adjacent tumor tissues (tissues of the negative surgical margin) and H8 cells, respectively. Higher miR-29b-2-5p expression correlated with a better 5-year progression-free survival of cervical cancer. MiR-29b-2-5p was also associated with the indicators (tumor size, tumor differentiation, FIGO (International Federation of Gynecology and Obstetrics) stage, and invasion depth) of the progression of cervical cancer tumors. And miR-29b-2-5p, along with tumor size, tumor differentiation, FIGO stage, histology type, and invasion depth, were independent prognostic factors for poor cervical cancer prognosis. MiR-29b-2-5p showed a suppressive effect on the proliferation, migration, and invasion of cervical cancer cells.</p><p><strong>Conclusions: </strong>MiR-29b-2-5p was downregulated in cervical cancer tumor tissues and could serve as an independent prognostic factor for cervical cancer. The overexpressed miR-29b-2-5p could be considered a tumor suppressor to inhibit the progression of cervical cancer.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":"39 4","pages":"319-327"},"PeriodicalIF":2.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142787525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating exosomal miRNA-451 as an effective diagnostic biomarker and prognostic indicator for multiple myeloma.","authors":"Jun Zhang, Cheng Luo, Haiying Long, Bin Zhang, Hongtao Shan, Benli Hou","doi":"10.1177/03936155241283747","DOIUrl":"10.1177/03936155241283747","url":null,"abstract":"<p><strong>Objective: </strong>Multiple myeloma (MM) is a plasma cell malignancy characterized by abnormal plasma cell proliferation in the bone marrow. Circulating exosomal miRNA-451 is associated with the progression of many tumors, but the relationship between its expression and MM has not been reported. In this study, we aimed to investigate the clinical value of miRNA-451 as a biomarker for diagnosis and prognosis of multiple myeloma.</p><p><strong>Methods: </strong>A total of 120 patients with multiple myeloma and 120 healthy control people were recruited in this study. The miRNA-451 expression in serum exosomes of participants was measured by quantitative real-time polymerase chain reaction, and the diagnostic value of miRNA-451 for multiple myeloma was assessed by receiver operating characteristic (ROC) curve. The correlation between miRNA-451 expression and plasma cells ratio and M protein content was analyzed by Pearson correlation coefficient. The prognosis of different miRNA-451 expression was evaluated by survival curves.</p><p><strong>Results: </strong>Results suggested that serum exosomal miRNA-451 expression was significantly decreased in patients with multiple myeloma rather than in the healthy controls. The ROC curve showed that area under the curve value of miRNA-451 was 0.888, suggesting that miRNA-451 had diagnostic value to multiple myeloma. Moreover, there was a negative correlation between miRNA-451 expression and plasma cells ratio or M protein content. Survival curves showed that patients with high miRNA-451 expression had a longer survival time, suggesting the value of miRNA-451 as a prognostic indicator of multiple myeloma.</p><p><strong>Conclusion: </strong>We demonstrated the relationship between miRNA-451 expression and multiple myeloma, indicating that miRNA-451 in circulating exosomes may be an effective diagnostic biomarker and prognostic indicator for multiple myeloma.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":" ","pages":"301-309"},"PeriodicalIF":2.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142299981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alteration of lncRNA RHPN1-AS1 predicts clinical prognosis and regulates the progression of bladder cancer via modulating miR-485-5p.","authors":"Jingmin Zhou, Jinshan Xu, Lin Cheng, Shuhui Li, Deqi Jiang, Jianchao Zhang, Yulong Sheng","doi":"10.1177/03936155241281076","DOIUrl":"10.1177/03936155241281076","url":null,"abstract":"<p><strong>Background: </strong>Exploring effect biomarkers that monitor tumor progression and predict the prognosis could benefit the clinical management of bladder cancer and improve the postoperative life of patients. This study aimed to estimate the function of long non-coding (lnc)RNA RHPN1-AS1 (RHPN1-AS1) in bladder cancer and the potential molecular mechanism.</p><p><strong>Methods: </strong>The expression of RHPN1-AS1 was evaluated in bladder cancer tissues from 115 patients and cells by polymerase chain reaction. The clinical significance of RHPN1-AS1 was assessed and its effect was also estimated in cell proliferation, migration, and invasion. The underlying molecular mechanism was explored by the dual-luciferase reporter assay.</p><p><strong>Results: </strong>The expression of RHPN1-AS1 was 2.91-fold elevated in bladder cancer, which showed a close correlation with advanced tumor node metastasis stage (<i>P </i>= 0.013) and the presence of lymph node metastasis (<i>P </i>= 0.018). RHPN1-AS1 also served as a poor prognostic indicator (hazard ratio = 2.563) for bladder cancer. The knockdown of RHPN1-AS1 significantly suppressed the proliferation and metastasis ability of bladder cancer cells. Moreover, miR-485-5p was found to mediate the function of RHPN1-AS1 in bladder cancer, which was considered the underlying regulatory mechanism.</p><p><strong>Conclusions: </strong>RHPN1-AS1 serves as a prognostic biomarker and tumor promoter in bladder cancer via modulating miR-485-5p, which might be a reliable target of bladder cancer therapy.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":" ","pages":"284-291"},"PeriodicalIF":2.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142134323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of metabolism-related markers on outcomes in ovarian cancer patients: Findings of the MITO16A/MaNGO-OV2 trial.","authors":"Stefano Indraccolo, Simona Signoriello, Ilaria Piga, Giovanni Esposito, Federica Ferrarini, Andrea Boscolo Bragadin, Vanda Salutari, Carmela Pisano, Daniela Califano, Eliana Bignotti, Germana Tognon, Vittorio Simeon, Grazia Artioli, Annamaria Ferrero, Saverio Cinieri, Alessandra Bologna, Paolo Chiodini, Giosuè Scognamiglio, Carolina Bottoni, Anna Spina, Daniela Russo, Laura Arenare, Francesco Perrone, Sandro Pignata","doi":"10.1177/03936155241296164","DOIUrl":"10.1177/03936155241296164","url":null,"abstract":"<p><strong>Introduction: </strong>In ovarian cancer, expression of metabolism-related markers has been investigated in several studies focusing on individual markers; however, a parallel quantitative evaluation of markers mapping to distinct metabolic processes and their prognostic value in large patient cohorts is still lacking.</p><p><strong>Methods: </strong>Here, by using immunohistochemistry followed by digital pathology, we investigated the expression of several markers related to glycolysis including monocarboxylate transporter 1 and 4 (MCT1, MCT4), glutamine metabolism (glutaminase, GLS) and hypoxia/acidosis (carbonic anhydrase 9, CA IX) in tissue microarrays of > 300 patients recruited in the MITO16A clinical trial, which involved treatment of ovarian cancer patients with carboplatin/taxol plus bevacizumab.</p><p><strong>Results: </strong>Regarding the prognostic impact of these markers, results indicate that GLS expression correlated with progression-free survival, but this effect disappeared when data were corrected for multiple testing. All other markers showed no correlation with clinical outcome.</p><p><strong>Conclusion: </strong>These results indicate marked heterogeneity of expression of metabolism-associated markers in ovarian cancer; however, there was a lack of association with clinical benefit after chemotherapy/anti-vascular endothelial growth factor treatment. Notwithstanding the lack of prognostic value, knowledge of the pattern of expression of these biomarkers in tumors can be useful for patient stratification purposes when new drugs targeting these metabolic pathways will be tested.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":" ","pages":"328-337"},"PeriodicalIF":2.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}